ALGS Insider Trading Activity and SEC Form 4 Filings
ALGS insider trading summary
No open-market insider purchases or sales of Aligos Therapeutics, Inc. (ALGS) have been reported on SEC Form 4 in the past 12 months.
Latest ALGS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 25, 2023 | Carole Nuechterlein | Insider | Buy | $6.0M (7,933,601 @ $0.76) |
| Oct 20, 2020 | Novo Holdings A/S | 10% Owner | Buy | $3.0M (200,000 @ $15.00) |
| Oct 20, 2020 | Versant Venture Capital VI, L.P. | 10% Owner | Buy | $3.0M (200,000 @ $15.00) |
| Oct 20, 2020 | Thomas Woiwode | Director | Buy | $3.0M (200,000 @ $15.00) |
| Oct 20, 2020 | Vivo Capital VIII, LLC | 10% Owner | Buy | $7.2M (483,267 @ $15.00) |
| Oct 20, 2020 | Vivo Capital Fund VIII, L.P. | 10% Owner | Buy | $7.2M (483,267 @ $15.00) |
| Oct 20, 2020 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Buy | $7.2M (483,267 @ $15.00) |
| Oct 20, 2020 | Versant Vantage I, L.P. | 10% Owner | Buy | $3.0M (200,000 @ $15.00) |
| Oct 20, 2020 | Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | Buy | $1.0M (66,733 @ $15.00) |
| Oct 20, 2020 | Vivo Capital VIII, LLC | 10% Owner | Buy | $1.0M (66,733 @ $15.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.